Angle PLC Announces Notice of AGM and Posting of Annual Report

GUILDFORD, SURREY / ACCESSWIRE / August 5, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that its Annual General Meeting (AGM) will be held at 2:00 pm on Thursday 27 August 2020 as a closed meeting at ANGLE plc, 10 Nugent Road, Surrey Research Park, Guildford, GU2 7AF. The AGM will be convened with the minimum necessary quorum of two shareholders with the Chief Executive and Finance Director attending in person while the rest of the Board attend remotely.

Due to the unprecedented situation with COVID-19 and in line with the UK Government's measures to maintain social distancing, shareholders and any other persons will not be permitted to attend the AGM in person or vote during the Meeting and shareholders are therefore strongly encouraged to submit their proxy votes online via www.signalshares.com or CREST where applicable. The AGM will be streamed online and shareholders will be able to watch the AGM remotely via an electronic platform, details of which are provided in the Notice of AGM.

The Company will also be hosting a business update presentation for shareholders after the formalities of the AGM are concluded. Shareholders may submit questions to the Board in advance of the AGM and business update presentation by email to [email protected] before 5.00 pm on Wednesday 26 August 2020. The Board will not be able to answer all individual questions but will Group the questions into themes and will endeavour to answer these during the presentation or as part of concluding matters.

The Annual Report and Accounts for the eight month period ended 31 December 2019 and Notice of AGM were posted to shareholders on 4 August 2020, both of which are available for download on the Company's website, www.angleplc.com

For further information:

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc www.angleplc.com

ANGLE is a world leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream analysis system for cost effective, highly multiplexed analysis of nucleic acids and proteins.

ANGLE's cell separation technology is called the Parsortix® system, and it enables a liquid biopsy (a simple blood test) to be used to provide the cells of interest to the user in a format suitable for multiple types of downstream analyses. The system is based on a microfluidic device that captures cells based on a combination of their size and compressibility. The system is epitope independent and can capture all types of CTCs as well as CTC clusters in a viable form (alive). CTCs enable the complete picture of a cancer to be seen as being a complete cell they allow DNA, RNA and protein analysis and the live cells harvested can be cultured. The Parsortix technology is the subject of 24 granted patents in Europe, the United States, China, Australia, Canada, India, Japan and Mexico with three extensive families of patents are being progressed worldwide. The Parsortix system has a CE Mark in Europe for the indicated use and FDA clearance is in process for the United States with a 400 subject clinical study and associated analytical studies in metastatic breast cancer. ANGLE is seeking to be the first ever FDA cleared CTC harvesting system and only the third ever FDA cleared liquid biopsy test. ANGLE has already undertaken two separate 200 subject clinical studies under a program designed to develop an ovarian cancer pelvic mass triage test, with the results showing best in class accuracy (AUC-ROC) of 95.1%. The pelvic mass triage assay has undergone further refinement and optimisation, and is currently in the process of a 200 patient clinical verification study.

ANGLE's technology for the multiplex evaluation of proteins and nucleic acids of all types is called the HyCEADTM Ziplex® platform and is based on a patented flow through array technology. It provides for low cost, highly multiplexed, rapid and sensitive capture of targets from a wide variety of sample types. A proprietary chemistry approach (the HyCEAD method) allows for the capture and amplification of over 100 biomarkers simultaneously in a single reaction. The HyCEAD Ziplex system is extremely sensitive and is ideal for measuring gene expression and other markers directly from Parsortix harvests and was used in the ovarian cancer pelvic mass triage test to achieve best in class accuracy (AUC-ROC) of 95.1%.

ANGLE's proprietary technologies can be combined to provide automated, sample-to-answer results in both centralised laboratory and point-of-use cartridge formats.

ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers. These Key Opinion Leaders (KOLs) are working to identify applications with medical utility (clear benefit to patients), and to secure clinical data that demonstrates that utility in patient studies. The body of evidence as to the benefits of the Parsortix system is growing rapidly from our own clinical studies in metastatic breast cancer and ovarian cancer and also from KOLs with 34 peer-reviewed publications and numerous publicly available posters, available on our website.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

SOURCE: Angle PLC